First‐in‐Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer

BACKGROUND. The purpose of this nonrandomized, open‐label, phase I study (NCT01285037) was to evaluate the safety and tolerability of merestinib, an oral antiproliferative and antiangiogenic kinase inhibitor, and to determine a recommended phase II dose and schedule for patients with advanced cancer...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: He, Aiwu Ruth, Cohen, Roger B., Denlinger, Crystal S., Sama, Ashwin, Birnbaum, Ariel, Hwang, Jimmy, Sato, Takami, Lewis, Nancy, Mynderse, Michelle, Niland, Michele, Giles, Jennifer, Wallin, Johan, Moser, Brian, Zhang, Wei, Walgren, Richard, Plimack, Elizabeth R.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
New Drug Development and Clinical Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738318/
https://ncbi.nlm.nih.gov/pubmed/30833489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0411
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars